As biomarkers such as circulating tumor cells (CTC), DNA repair gene alterations, and androgen receptor splice variants become more widely implemented in clinical practice, ITB and MTB discussions will play a pivotal role in guiding personalized treatment for mCRPC (Slootbeek et al. 2022; Asif and Teply 2021). The gene discussed is AR; the disease is neoplasm.